<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462720</url>
  </required_header>
  <id_info>
    <org_study_id>VAP.VV018</org_study_id>
    <nct_id>NCT02462720</nct_id>
  </id_info>
  <brief_title>COMFORT: A Multicenter, Open-label, Randomized, Crossover Study</brief_title>
  <acronym>COMFORT</acronym>
  <official_title>Multicenter Study to Evaluate Pain Following Treatment of Varicose Vein With Varithena® Compared to Radiofrequency Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BTG International Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BTG International Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate pain the patient experienced following treatment of
      varicose veins with Varithena® compared to radiofrequency ablation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A study that evaluates pain following treatment of varicose veins in patients treated with
      Varithena® and those treated with RFA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>14 day average (0-100)</time_frame>
    <description>14-day average post-treatment pain using a VAS pain score. VAS pain score is an integer-valued, interval scale variable with range from 0 to 100 representing the spectrum from no pain to pain as bad as one can imagine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural Pain</measure>
    <time_frame>immediately following procedure</time_frame>
    <description>degree of procedural pain perceived by the patient obtained immediately following the procedure using a VAS pain score. VAS pain score is an integer-valued, interval scale variable with range from 0 to 100 representing the spectrum from no pain to pain as bad as one can imagine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Preference</measure>
    <time_frame>8 weeks</time_frame>
    <description>Patient preference for RFA or Varithena® using e-diary</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Varicose Veins</condition>
  <arm_group>
    <arm_group_label>Varithena®, then Radiofrequency Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varithena (polidocanol injectable foam) supplied as polidocanol solution 180 mg/18 mL (10 mg/mL) to be activated before use. Once activated, Varithena is a white injectable foam delivering a 1% polidocanol solution. Each milliliter of Varithena injectable foam contains 1.3 mg of polidocanol. Up to 5 mL per injection or 15 mL per treatment session could be used. This was followed by RFA treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiofrequency ablation then Varithena</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RFA procedures were conducted in accordance with the physician's standard of care and according to the manufacturer's instructions for use. This was followed by treatment with Varithena.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varithena®</intervention_name>
    <description>Varithena® treatment in accordance with full prescribing information and instructions for use</description>
    <arm_group_label>Varithena®, then Radiofrequency Ablation</arm_group_label>
    <arm_group_label>Radiofrequency ablation then Varithena</arm_group_label>
    <other_name>Polidocanol Solution, 180 mg/18 mL (10 mg/mL)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiofrequency ablation</intervention_name>
    <description>Radiofrequency ablation conducted per physicians' standard of care.</description>
    <arm_group_label>Varithena®, then Radiofrequency Ablation</arm_group_label>
    <arm_group_label>Radiofrequency ablation then Varithena</arm_group_label>
    <other_name>RFA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women; age 18 to 75 years

          2. Bilateral incompetence of SFJ (reflux &gt;1 second on duplex ultrasonography) associated
             with incompetence of the GSV in both legs

          3. GSV diameter &gt;5 mm measured from the superficial epigastric vein to 10 cm below the
             SFJ while in a standing position in both legs

          4. Eligible to receive RFA treatment and Varithena® treatment

          5. CEAP C2-C5 (inclusive)

          6. Patient is participating in usual work and home activities with no changes anticipated
             for the duration of the study

          7. Ability to comprehend and sign an informed consent and complete study questionnaires
             written in English

          8. Ability to reliably use an electronic diary to record pain and analgesic/opioid use in
             accordance with the protocol

        Exclusion Criteria:

          1. Prior GSV treatment in either leg

          2. Non-venous source of pain in either leg that could confound the results of the study

          3. Use of chronic analgesic or opiate medications or medical history that could result in
             the regular use of pain medications during the study

          4. History of deep vein thrombosis, pulmonary embolism or stroke, including evidence of
             prior or active DVT on duplex ultrasound

          5. Deep venous reflux unless clinically insignificant in comparison to superficial reflux

          6. Inability to wear post-procedure compression bandaging and stockings

          7. Reduced mobility (unable to walk unaided for 5 minutes per waking hour)

          8. Major surgery, prolonged hospitalization or pregnancy within 3 months of screening

          9. Major co-existing disease (e.g., malignancy; pulmonary disease; renal or hepatic
             insufficiency; serious skin disease/condition that may compromise the ability of the
             patient to comply with the compression protocol, etc.)

         10. Contraindications to Varithena® (e.g., acute thromboembolic disease) or RFA according
             to the manufacturer's prescribing information

               1. Varithena® contraindication due to known allergy to polidocanol

               2. RFA contraindication due to veins being too large

               3. RFA Contraindication due to veins being too tortuous

         11. Known allergic response to polidocanol and/or multiple allergic reactions

         12. Current or history of alcohol or drug abuse

         13. Pregnant or lactating women

         14. Women of childbearing potential not using effective contraception for at least one
             month prior to study treatment and/or unwilling to continue birth control for the
             duration of the study

         15. Participation in a clinical study involving an investigational pharmaceutical product
             or device within the 3 months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Wright, MD</last_name>
    <role>Study Director</role>
    <affiliation>BTG International Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coastal Vascular and Interventional, PLLC</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Institute for Minimally Invasive Therapies</name>
      <address>
        <city>Melrose Park</city>
        <state>Illinois</state>
        <zip>60160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Venous Institute of Buffalo</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Washington Vascular</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2015</study_first_submitted>
  <study_first_submitted_qc>June 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <results_first_submitted>January 18, 2017</results_first_submitted>
  <results_first_submitted_qc>January 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 23, 2018</results_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Veins</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polidocanol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Varithena® First Then Radiofrequency Ablation</title>
          <description>Patients receive Varithena® treatment first in one leg, with 4-week follow-up period in Part 1; followed by Radiofrequency ablation in the other leg in Part 2.
Varithena® treatment administered in accordance with full prescribing information and instructions for use.
Radiofrequency ablation conducted per physicians' standard of care</description>
        </group>
        <group group_id="P2">
          <title>Radiofrequency Ablation First Than Varithena</title>
          <description>Patients will receive radiofrequency ablation treatment first in one leg, with 4-week follow-up period in Part 1; followed by Varithena® in the other leg in Part 2.
Varithena® treatment administered in accordance with full prescribing information and instructions for use.
Radiofrequency ablation conducted per physicians' standard of care</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Varithena®</title>
          <description>Varithena®: Varithena® treatment in accordance with full prescribing information and instructions for use followed by Radiofrequency ablation: Radiofrequency ablation conducted per physicians' standard of care.
Radiofrequency ablation: Radiofrequency ablation conducted per physicians' standard of care followed by Varithena®: Varithena® treatment in accordance with full prescribing information and instructions for use</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.9" spread="11.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain</title>
        <description>14-day average post-treatment pain using a VAS pain score. VAS pain score is an integer-valued, interval scale variable with range from 0 to 100 representing the spectrum from no pain to pain as bad as one can imagine.</description>
        <time_frame>14 day average (0-100)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varithena®</title>
            <description>Varithena (polidocanol injectable foam) supplied as polidocanol solution 180 mg/18 mL (10 mg/mL) to be activated before use. Once activated, Varithena is a white injectable foam delivering a 1% polidocanol solution. Each milliliter of Varithena injectable foam contains 1.3 mg of polidocanol. Up to 5 mL per injection or 15 mL per treatment session could be used.
Varithena®: Varithena® treatment in accordance with full prescribing information and instructions for use
Radiofrequency ablation: Radiofrequency ablation conducted per physicians' standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Radiofrequency Ablation</title>
            <description>RFA procedures were conducted in accordance with the physician’s standard of care and according to the manufacturer’s instructions for use.
Varithena®: Varithena® treatment in accordance with full prescribing information and instructions for use
Radiofrequency ablation: Radiofrequency ablation conducted per physicians' standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>14-day average post-treatment pain using a VAS pain score. VAS pain score is an integer-valued, interval scale variable with range from 0 to 100 representing the spectrum from no pain to pain as bad as one can imagine.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="2.90"/>
                    <measurement group_id="O2" value="9.5" spread="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Pain</title>
        <description>degree of procedural pain perceived by the patient obtained immediately following the procedure using a VAS pain score. VAS pain score is an integer-valued, interval scale variable with range from 0 to 100 representing the spectrum from no pain to pain as bad as one can imagine</description>
        <time_frame>immediately following procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varithena®</title>
            <description>Varithena® treatment in accordance with full prescribing information and instructions for use
Radiofrequency ablation: Radiofrequency ablation conducted per physicians' standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Radiofrequency Ablation</title>
            <description>Varithena® treatment in accordance with full prescribing information and instructions for use
Radiofrequency ablation: Radiofrequency ablation conducted per physicians' standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Pain</title>
          <description>degree of procedural pain perceived by the patient obtained immediately following the procedure using a VAS pain score. VAS pain score is an integer-valued, interval scale variable with range from 0 to 100 representing the spectrum from no pain to pain as bad as one can imagine</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" spread="3.53"/>
                    <measurement group_id="O2" value="17.8" spread="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Preference</title>
        <description>Patient preference for RFA or Varithena® using e-diary</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varithena®</title>
            <description>Varithena® treatment in accordance with full prescribing information and instructions for use
Radiofrequency ablation: Radiofrequency ablation conducted per physicians' standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Radiofrequency Ablation</title>
            <description>Varithena® treatment in accordance with full prescribing information and instructions for use
Radiofrequency ablation: Radiofrequency ablation conducted per physicians' standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Preference</title>
          <description>Patient preference for RFA or Varithena® using e-diary</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>A period of time ending at Week 4 (day 32)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Varithena®</title>
          <description>Varithena® treatment in accordance with full prescribing information and instructions for use
Radiofrequency ablation: Radiofrequency ablation conducted per physicians' standard of care.</description>
        </group>
        <group group_id="E2">
          <title>Radiofrequency Ablation</title>
          <description>Varithena® treatment in accordance with full prescribing information and instructions for use
Radiofrequency ablation: Radiofrequency ablation conducted per physicians' standard of care.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lynn Allen</name_or_title>
      <organization>BTG International Inc.</organization>
      <phone>425-410-3152</phone>
      <email>lynn.allen@btgplc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

